Top Industry Leaders in the Pemphigus Market
Latest Pemphigus Companies Updates:
Argenx: Their investigational drug necuparanumab (ARGX-113) met its primary endpoint in a Phase 3 trial for pemphigus vulgaris, showing statistically significant improvement in blister severity compared to placebo. This paves the way for potential regulatory approval and market entry.
Viela Bio: Their anti-IL-17A antibody inebilizumab (VIB488) demonstrated positive Phase 2b data for treating pemphigus vulgaris, with significant reductions in blister count and steroid use. They're planning Phase 3 trials to confirm these findings.
Amgen's Saphnelo (rituximab-pvvr) received expanded FDA approval for maintenance treatment of adults with pemphigus vulgaris, offering a longer-term management option.
AstraZeneca's Soliris (eculizumab) gained approval in China for treating adult patients with refractory generalized myasthenia gravis (gMG) and anti-acetylcholine receptor (AChR) antibody positivity. While not directly for Pemphigus, this opens doors for wider access to the complement inhibitor with potential benefits for Pemphigus patients as well.
Sanofi acquired Amunix Pharmaceuticals, gaining access to their IL-17A inhibitor AMX-141, which holds promise for Pemphigus treatment.
UCB and Kiniksa Pharmaceuticals entered into a collaboration to develop and commercialize Kiniksa's investigational anti-GM-CSF antibody KHX242 for treating inflammatory diseases, including Pemphigus.
List of Pemphigus Key companies in the market:
- Novartis Pharmaceuticals
- Hoffmann-La Roche
- Principia Biopharma, Inc
- Argenx
- Sanofi S.A
- Pfizer Inc
- Teligent Inc
- GlaxoSmithKline LLC
- Teva Pharmaceutical Industries.
